Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 435

Results For "IT"

10487 News Found

Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
News | March 31, 2026

Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy

Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively


Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
News | March 30, 2026

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology


Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
R&D | March 29, 2026

Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I

The approval covers pediatric patients without a matched sibling donor for stem cell transplant


Philips launches game-changing interventional platform for cardiology
News | March 29, 2026

Philips launches game-changing interventional platform for cardiology

IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision


Shreehas Tambe appointed CEO & Managing Director of Biocon
People | March 28, 2026

Shreehas Tambe appointed CEO & Managing Director of Biocon

Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited


Eli Lilly drug shows 4-year relief for eczema patients, study finds
R&D | March 28, 2026

Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection


AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials
Clinical Trials | March 28, 2026

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo


Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal
News | March 28, 2026

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones


Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
Drug Approval | March 28, 2026

Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets

Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder


Novartis acquires Excellergy to bolster allergy portfolio
News | March 28, 2026

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments